Table 2: EULAR responses at next reevaluation after first RA flare.

EULAR response
NoModerateGood

RTX
 Group A4 (16%)5 (20%)7 (28%)0.038
 Group B6 (24%)2 (10%)1 (4%)
IFX
 Group A2 (10%)5 (25%)2 (10%)0.002
 Group B10 (50%)1 (5%)0
ETN
 Group A3 (16.67%)5 (27.78%)7 (38.89%)0.023
 Group B3 (16.67%)00
ADL
 Group A2 (22.22%)1 (11.11%)5 (55.56%)0.194
 Group B1 (11.11%)00

Differences between EULAR responses in group A and group B were tested using Kruskal-Wallis test, for each biologic agent.
RTX: rituximab; IFX: infliximab; ETN: etanercept; ADL: adalimumab.
Group A: detectable drug level; Group B: undetectable drug level.